S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
The Next Stage Of Google’s Rally Just Started
66,000% upside on tiny biotech? (Ad)
Can Investors Win the Race with Dividend Achiever Nike?
CarMax Slides On Earnings Disappointment, Time To Celebrate?
66,000% upside on tiny biotech? (Ad)
Costco Isn't Facing Devastating Surges in Theft Like Target and Walmart — and the Reason Is Very Simple
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
This Stock Could Go Up 66% or More. (Ad)
4 Proven Strategies to Help You Find Success in Executive Leadership
'Control, Surveillance and Manipulation': How TikTok's Office Surveillance Could Backfire and Cost The Company Billions
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
The Next Stage Of Google’s Rally Just Started
66,000% upside on tiny biotech? (Ad)
Can Investors Win the Race with Dividend Achiever Nike?
CarMax Slides On Earnings Disappointment, Time To Celebrate?
66,000% upside on tiny biotech? (Ad)
Costco Isn't Facing Devastating Surges in Theft Like Target and Walmart — and the Reason Is Very Simple
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
This Stock Could Go Up 66% or More. (Ad)
4 Proven Strategies to Help You Find Success in Executive Leadership
'Control, Surveillance and Manipulation': How TikTok's Office Surveillance Could Backfire and Cost The Company Billions
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
The Next Stage Of Google’s Rally Just Started
66,000% upside on tiny biotech? (Ad)
Can Investors Win the Race with Dividend Achiever Nike?
CarMax Slides On Earnings Disappointment, Time To Celebrate?
66,000% upside on tiny biotech? (Ad)
Costco Isn't Facing Devastating Surges in Theft Like Target and Walmart — and the Reason Is Very Simple
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
This Stock Could Go Up 66% or More. (Ad)
4 Proven Strategies to Help You Find Success in Executive Leadership
'Control, Surveillance and Manipulation': How TikTok's Office Surveillance Could Backfire and Cost The Company Billions
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
The Next Stage Of Google’s Rally Just Started
66,000% upside on tiny biotech? (Ad)
Can Investors Win the Race with Dividend Achiever Nike?
CarMax Slides On Earnings Disappointment, Time To Celebrate?
66,000% upside on tiny biotech? (Ad)
Costco Isn't Facing Devastating Surges in Theft Like Target and Walmart — and the Reason Is Very Simple
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
This Stock Could Go Up 66% or More. (Ad)
4 Proven Strategies to Help You Find Success in Executive Leadership
'Control, Surveillance and Manipulation': How TikTok's Office Surveillance Could Backfire and Cost The Company Billions
NASDAQ:STSA

Satsuma Pharmaceuticals (STSA) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$1.01
▼
$1.14
50-Day Range
$1.04
▼
$1.11
52-Week Range
$0.59
▼
$8.08
Volume
1.83 million shs
Average Volume
701,788 shs
Market Capitalization
$36.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.75
ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial MediaSustainability

Satsuma Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
422.7% Upside
$5.75 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-1.25
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.82) to ($0.89) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

377th out of 973 stocks

Pharmaceutical Preparations Industry

160th out of 452 stocks

See Top Rated MarketRank™ Stocks Here

STSA stock logo

About Satsuma Pharmaceuticals (NASDAQ:STSA) Stock

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.


STSA Stock News Headlines

August 30, 2023 | usnews.com
Satsuma City High School
June 9, 2023 | bizjournals.com
Japanese pharma acquires its crash-strapped Durham spin-out
September 30, 2023 | Behind the Markets (Ad)
Jeff Bezos Backs "Drug Smuggler" to Fight Alzheimer's
A small, publicly traded biotech is racing to the discovery of a lifetime: Using a Drug Smuggler to Fight Alzheimer's, Parkinson's and Dementia. This radical treatment is so promising, Biogen, Sanofi and Genentech paid $1 billion to license it. Click here to learn more >>>
June 8, 2023 | bizjournals.com
Japanese pharma acquires its Durham spin-out
May 18, 2023 | finance.yahoo.com
Satsuma Pharmaceuticals Announces FDA Acceptance of 505(b)(2) NDA for STS101, a Novel and Investigational Dihydroergotamine (DHE) Nasal Powder Product for the Acute Treatment of Migraine
May 3, 2023 | marketwatch.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TESS, STSA, CHRA
May 1, 2023 | benzinga.com
Shareholder Alert: Ademi LLP investigates whether Satsuma Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Shin Nippon
April 25, 2023 | marketwatch.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NATI, RXDX, STSA, CHRA
September 30, 2023 | Behind the Markets (Ad)
Jeff Bezos Backs "Drug Smuggler" to Fight Alzheimer's
A small, publicly traded biotech is racing to the discovery of a lifetime: Using a Drug Smuggler to Fight Alzheimer's, Parkinson's and Dementia. This radical treatment is so promising, Biogen, Sanofi and Genentech paid $1 billion to license it. Click here to learn more >>>
April 22, 2023 | seekingalpha.com
STSA Satsuma Pharmaceuticals, Inc.
April 21, 2023 | finance.yahoo.com
Satsuma Pharmaceuticals Announces Three Abstracts Accepted at The 75th American Academy of Neurology Annual Meeting
April 19, 2023 | msn.com
After Satsuma Pharma Rockets 65% on SNBL Bid, There Could Still Be 6X More Upside
April 18, 2023 | marketwatch.com
Satsuma Pharmaceuticals Shares Soar on Shin Nippon Biomedical Deal >STSA
April 17, 2023 | benzinga.com
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Satsuma Pharmaceuticals, Inc. Buyout
April 17, 2023 | bizjournals.com
Peninsula company bets big part of potential $221M sale on future of migraine drug
April 17, 2023 | markets.businessinsider.com
Satsuma Pharma Agrees To Be Acquired By Shin Nippon Biomedical
April 17, 2023 | msn.com
Satsuma Skyrockets after Acquisition by Shin Nippon
April 17, 2023 | investorplace.com
Why Is Satsuma Pharmaceuticals (STSA) Stock Up 144% Today?
April 16, 2023 | finance.yahoo.com
SNBL to Acquire Satsuma Pharmaceuticals
March 30, 2023 | markets.businessinsider.com
H.C. Wainwright Reaffirms Their Buy Rating on Satsuma Pharmaceuticals (STSA)
March 30, 2023 | finance.yahoo.com
We're A Little Worried About Satsuma Pharmaceuticals' (NASDAQ:STSA) Cash Burn Rate
March 29, 2023 | bizjournals.com
Migraine drug maker seeks FDA approval and a partner as it cuts jobs
March 28, 2023 | finance.yahoo.com
Satsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
February 18, 2023 | marketwatch.com
8-K: Satsuma Pharmaceuticals, Inc.
February 7, 2023 | reuters.com
STSA.O
February 2, 2023 | finance.yahoo.com
Satsuma Pharmaceuticals to Participate in the Virtual SVB Securities Global Biopharma Conference
December 28, 2022 | finance.yahoo.com
Despite Trial Failure, Satsuma Pharma Says Its Migraine Candidate Has Potential For Approval
See More Headlines
Receive STSA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Satsuma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

STSA Company Calendar

Last Earnings
11/09/2021
Today
9/30/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
Regional Banks
Sector
Medical
Current Symbol
NASDAQ:STSA
CUSIP
85931930
CIK
891106
Web
www.satsumarx.com
Phone
650-410-3200
Fax
N/A
Employees
21
Year Founded
2016

Price Target and Rating

Average Stock Price Forecast
$5.75
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+422.7%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
4 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.01)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-70,060,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-115.24%
Return on Assets
-102.26%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.44
Quick Ratio
7.44

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.41 per share
Price / Book
0.78

Miscellaneous

Outstanding Shares
33,150,000
Free Float
22,809,000
Market Cap
$36.47 million
Optionable
Not Optionable
Beta
0.10

Social Links

20 Stocks to Sell Now Cover
20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. John A. Kollins MBA (Age 59)
    Pres, CEO & Director
    Comp: $830k
  • Mr. Thomas P. O'Neil (Age 57)
    Chief Financial Officer
    Comp: $550.08k
  • Dr. Detlef F. Albrecht (Age 61)
    Chief Medical Officer
    Comp: $625.97k
  • Mr. Mic Iwashima (Age 44)
    VP & Head of Operations
  • Mr. Robert Schultz (Age 58)
    Sr. VP & Head of Chemistry, Manufacturing and Controls
  • Dr. Shannon Strom Ph.D. (Age 46)
    VP & Head of Regulatory Affairs
  • Mr. Robert M. Janosky
    Chief Commercial Officer

Key Competitors

View All Competitors

Insiders

View All Insider Transactions













STSA Stock - Frequently Asked Questions

Should I buy or sell Satsuma Pharmaceuticals stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Satsuma Pharmaceuticals in the last year. There are currently 4 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" STSA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in STSA, but not buy additional shares or sell existing shares.
View STSA analyst ratings or view top-rated stocks.

What is Satsuma Pharmaceuticals' stock price forecast for 2023?

4 brokers have issued 1-year target prices for Satsuma Pharmaceuticals' shares. Their STSA share price forecasts range from $2.00 to $15.00. On average, they expect the company's share price to reach $5.75 in the next year. This suggests a possible upside of 422.7% from the stock's current price.
View analysts price targets for STSA or view top-rated stocks among Wall Street analysts.

How were Satsuma Pharmaceuticals' earnings last quarter?

Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) issued its quarterly earnings results on Tuesday, November, 9th. The financial services provider reported ($0.42) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.51) by $0.09.

What other stocks do shareholders of Satsuma Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Satsuma Pharmaceuticals investors own include Verrica Pharmaceuticals (VRCA), AbbVie (ABBV), Adaptimmune Therapeutics (ADAP), Alector (ALEC), Dynavax Technologies (DVAX), Homology Medicines (FIXX), Gilead Sciences (GILD), Novan (NOVN), Pfizer (PFE) and Akebia Therapeutics (AKBA).

When did Satsuma Pharmaceuticals IPO?

(STSA) raised $75 million in an initial public offering on Friday, September 13th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Credit Suisse, SVB Leerink and Evercore acted as the underwriters for the IPO.

What is Satsuma Pharmaceuticals' stock symbol?

Satsuma Pharmaceuticals trades on the NASDAQ under the ticker symbol "STSA."

What is Satsuma Pharmaceuticals' stock price today?

One share of STSA stock can currently be purchased for approximately $1.10.

How much money does Satsuma Pharmaceuticals make?

Satsuma Pharmaceuticals (NASDAQ:STSA) has a market capitalization of $36.47 million. The financial services provider earns $-70,060,000.00 in net income (profit) each year or ($2.01) on an earnings per share basis.

How can I contact Satsuma Pharmaceuticals?

Satsuma Pharmaceuticals' mailing address is 400 OYSTER POINT BOULEVARD SUITE 221, SOUTH SAN FRANCISCO CA, 64080. The official website for the company is www.satsumarx.com. The financial services provider can be reached via phone at 650-410-3200 or via email at cdavis@lifesciadvisors.com.

This page (NASDAQ:STSA) was last updated on 9/30/2023 by MarketBeat.com Staff

My Account -